Serina Therapeutics (SER) Investor presentation summary

Platform overview

• POZ Platform enables next-generation drug product optimization for multiple modalities, including small molecules, RNA, and ADC/AOC therapies.

• Platform supports improved targeting, delivery, and reduced immunogenicity for RNA and cancer therapies, with collaborations such as Pfizer in mRNA.

• Proprietary assets and partnering opportunities are being pursued across therapeutic areas.

Small molecule pipeline and development

• Lead candidates include SER-252 (POZ-apomorphine) for advanced Parkinson's, SER-270 (POZ-VMAT2i) for tardive dyskinesia, and SER-290 for an undisclosed CNS indication.

• SER-252 is advancing to a Phase 1b registrational trial with first patient in expected 1Q 2026.

• SER-270 and SER-290 are targeting IND-enabling studies in 2026, with significant market opportunities.

POZ technology and delivery advantages

• POZ enables continuous drug delivery via a cleavable linker and enzymatic release, allowing for weekly subcutaneous injections with near zero-order kinetics.

• Human PK proof-of-concept established with prior candidate, showing equivalence to listed drugs and no adverse events.

• The enFuse device, already FDA approved, enables convenient, on-body administration without the need for healthcare provider involvement.